Stock Track | Hengrui Pharma Soars 5.83% Intraday on Major $15.2 Billion Deal with Bristol-Myers Squibb

Stock Track05-12

Hengrui Pharma's stock surged 5.83% during intraday trading on Tuesday, following the announcement of a landmark global strategic collaboration.

The company has entered into collaboration and license agreements with Bristol-Myers Squibb to jointly advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology. Under the terms, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, with the potential total value of the agreements reaching approximately $15.2 billion upon achievement of all development, regulatory, and commercial milestones.

The partnership grants BMS exclusive global rights to Hengrui-originated projects outside Mainland China, Hong Kong, and Macau, while Hengrui secures exclusive rights to BMS-originated programs within those territories. This significant deal is expected to accelerate the development of innovative medicines and validates Hengrui's research capabilities, driving investor optimism.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158235935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 13:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158235935","market":"us","top_or_hot":-1,"title":"Stock Track | Hengrui Pharma Soars 5.83% Intraday on Major $15.2 Billion Deal with Bristol-Myers Squibb","media":"Stock Track","content":"<p>Hengrui Pharma's stock surged 5.83% during intraday trading on Tuesday, following the announcement of a landmark global strategic collaboration.</p><p>The company has entered into collaboration and license agreements with Bristol-Myers Squibb to jointly advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology. Under the terms, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, with the potential total value of the agreements reaching approximately $15.2 billion upon achievement of all development, regulatory, and commercial milestones.</p><p>The partnership grants BMS exclusive global rights to Hengrui-originated projects outside Mainland China, Hong Kong, and Macau, while Hengrui secures exclusive rights to BMS-originated programs within those territories. This significant deal is expected to accelerate the development of innovative medicines and validates Hengrui's research capabilities, driving investor optimism.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hengrui Pharma Soars 5.83% Intraday on Major $15.2 Billion Deal with Bristol-Myers Squibb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hengrui Pharma Soars 5.83% Intraday on Major $15.2 Billion Deal with Bristol-Myers Squibb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 13:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hengrui Pharma's stock surged 5.83% during intraday trading on Tuesday, following the announcement of a landmark global strategic collaboration.</p><p>The company has entered into collaboration and license agreements with Bristol-Myers Squibb to jointly advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology. Under the terms, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, with the potential total value of the agreements reaching approximately $15.2 billion upon achievement of all development, regulatory, and commercial milestones.</p><p>The partnership grants BMS exclusive global rights to Hengrui-originated projects outside Mainland China, Hong Kong, and Macau, while Hengrui secures exclusive rights to BMS-originated programs within those territories. This significant deal is expected to accelerate the development of innovative medicines and validates Hengrui's research capabilities, driving investor optimism.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1158235935","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158235935","pubTimestamp":1778562591,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hengrui Pharma's stock surged 5.83% during intraday trading on Tuesday, following the announcement of a landmark global strategic collaboration.The company has entered into collaboration and license...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"个股追踪|恒瑞医药盘中大涨5.83%与百时美施贵宝达成152亿美元重大交易","themeId":"b1f4c1fa965d76d4e78087079f689b4e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Hengrui Pharma's stock surged 5.83% during intraday trading on Tuesday, following the announcement of a landmark global strategic collaboration.The company has entered into collaboration and license agreements with Bristol-Myers Squibb to jointly advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology. Under the terms, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, with the potential total value of the agreements reaching approximately $15.2 billion upon achievement of all development, regulatory, and commercial milestones.The partnership grants BMS exclusive global rights to Hengrui-originated projects outside Mainland China, Hong Kong, and Macau, while Hengrui secures exclusive rights to BMS-originated programs within those territories. This significant deal is expected to accelerate the development of innovative medicines and validates Hengrui's research capabilities, driving investor optimism.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158235935","isCrawlerRequest":true}